SOURCE: Spencer Pharmaceutical, Inc.

November 17, 2010 09:00 ET

Spencer Pharmaceutical Releases Scientific Results

BOSTON, MA--(Marketwire - November 17, 2010) -  Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announced today that it has released some of its scientific results.

The company states that chronic inflammation is closely related to many diseases and conditions associated with aging as well as arthritis, gastric reflux disease, colitis, some forms of cancer, Alzheimer's disease, immune dysfunction, etc. There is a great need for effective treatments that will be simple with no adverse side effects.

Generally, Ibuprofen (OTC) is rapidly absorbed following oral administration, and possesses a plasma half-life of approximately 2 hours with 80 % of the administered dose excreted in urine. Consequently, the immediate-release dosage of ibuprofen is 200 mg every 4-6 h, with a maximum dosage of 1200 mg over 24 hours. In simple language, there is a big demand on the market for slow release Ibuprofen. 

"Spencer Pharmaceutical has developed such a slow release and unique formulation for NSAIDs controlled release, particularly Ibuprofen, under direct compression on monolithic tablet format, which are able to deliver immediately an effective dosage of the molecule and the remained dosage over a delayed period of 8-10 hours," stated Dr. Max Arella, CEO of Spencer Pharmaceutical Inc. Furthermore "The matrix (excipient) is based on natural molecules and stabilized under ionic forms. All ingredients are 100 % GRAS (generally approved as safe) and already approved as acceptable substances by FDA," pointed out Dr. Arella.

The company also points out, in vitro dissolution showed the novel monolithic tablet (600 mg) of ibuprofen is rapidly delivered in simulated gastric fluid (SGF, pH 2.0) with approximately 25 % released during the first hour and the remaining dosage of ibuprofen is sustained for released over the remaining 10 hours. The easy and non-expensive matrix developed by Spencer Pharmaceutical is currently being submitted for patent protection.

"We are excited by these new results and we are confident that many applications will be found for this new matrix developed by our scientists," commented Dr. Max Arella, CEO of Spencer Pharmaceutical.

About Spencer Pharmaceutical Inc.

Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.

Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.

Contact Information

  • Contact:
    Dr. Max Arella
    Spencer Pharmaceutical Inc.
    Tel. 1+(617) 973-5017